Phathom Pharmaceuticals Inc

Intermediate bearish pressure remains dominant for PHAT as price trades below declining EMAs with repeated rejection at moving average resistance, favoring selling into failed relief rallies around the 9/21/50 EMA confluence for tactical downside participation while acknowledging the longer-term uptrend.

• ↑Q1 revenue rose 104% YoY to $58.3M, driven by Voquezna adoption
• ↑Voquezna fills surged 115% YoY to 1.35M, capturing 45% market share
• ↓Q1 loss of $9.9M and negative earnings yield hamper margin expansion